1. Chemical impurities: an epistemological riddle with serious side effects;Abdin;Int. J. Environ. Res. Public Health,2020
2. European Medicines Agency, International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH Q1A(R2), Stability Testing of New Drug Substances and Products. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf, 2003 (accessed 23 August 2022).
3. A graphical journey of innovative organic architectures that have improved our lives;McGrath;J. Chem. Ed.,2010
4. Valsartan: a novel angiotensin Type 1 receptor antagonist;Thurmann;Expert Opin. Pharmacother.,2000
5. European Medicines Agency, Update on review of valsartan medicines following detection of impurity in active substance – assessing potential impact on patients is priority. https://www.ema.europa.eu/en/news/update-review-valsartan-medicines-following-detection-impurity-active-substance-assessing-potential, 2018 (accessed 23 August 2022).